Table 2.
Baseline characteristics for patients in training and validation sets with complete case analysis
| Baseline characteristics | Training set |
P value | Training set (n = 182) |
Validation set (n = 566) |
P value | |
|---|---|---|---|---|---|---|
| CNS relapse cohort (n = 63) |
University of Pennsylvania control cohort (n = 119) |
|||||
| Median (range) | Median (range) | |||||
| Age, y | 62 (24-81) | 58 (20-85) | .161 | 60 (20-85) | 65 (18-94) | <.001 |
| Age | n (%) | n (%) | ||||
| >60 y | 35 (56) | 55 (46) | .276 | 90 (49) | 366 (65) | <.001 |
| ≤60 y | 28 (44) | 64 (54) | 92 (51) | 200 (35) | ||
| Sex | ||||||
| Male | 38 (60) | 67 (56) | .639 | 105 (58) | 345 (61) | .435 |
| Female | 25 (40) | 52 (44) | 77 (42) | 221 (39) | ||
| MTNKN histology | ||||||
| PTCL, NOS | 25 (40) | 17 (14) | <.001 | 42 (23) | 195 (35) | .004 |
| TFH-TCL (includes AITL) | 14 (22) | 31 (26) | .594 | 45 (25) | 84 (15) | .003 |
| ALCL, ALK+ | 1 (2) | 17 (14) | .007 | 18 (10) | 50 (9) | .658 |
| ALCL, ALK– | 9 (14) | 17 (14) | 1 | 26 (14) | 93 (16) | .561 |
| ALCL, ALKu | 0 (0) | 0 (0) | 1 | 0 (0) | 27 (5) | .001 |
| ENKTL | 5 (8) | 14 (12) | .611 | 19 (10) | 24 (4) | .003 |
| SPTCL (includes SPTCL and PCGD-TCL) | 2 (3) | 13 (11) | .091 | 15 (8) | 9 (2) | <.001 |
| EATL (includes EATL and MEITL) | 6 (10) | 2 (2) | .021 | 8 (4) | 48 (9) | .075 |
| HSTCL | 1 (2) | 5 (4) | .666 | 6 (3) | 8 (1) | .118 |
| TCL UNS | 0 (0) | 0 (0) | 1 | 0 (0) | 28 (5) | <.001 |
| ALCL, BIA | 0 (0) | 3 (3) | .552 | 3 (2) | 0 (0) | .014 |
| ECOG PS | .851 | .12 | ||||
| 2-4 | 14 (22) | 25 (21) | 39 (21) | 156 (28) | ||
| 0-1 | 49 (78) | 94 (79) | 143 (79) | 410 (72) | ||
| Elevated LDH | .271 | .728 | ||||
| Yes | 41 (65) | 67 (56) | 108 (59) | 344 (61) | ||
| No | 22 (35) | 52 (44) | 74 (41) | 222 (39) | ||
| Ann Arbor stage | .043 | .415 | ||||
| III or IV | 50 (79) | 77 (65) | 127 (70) | 375 (66) | ||
| I or II | 13 (21) | 42 (35) | 55 (30) | 191 (34) | ||
| B symptoms | .435 | <.001 | ||||
| Yes | 30 (48) | 49 (41) | 79 (43) | 340 (60) | ||
| No | 33 (52) | 70 (59) | 103 (57) | 226 (40) | ||
| Site of EN involvement (excluding BM/PB) | ||||||
| None | 19 (30) | 54 (45) | .057 | 73 (40) | 248 (44) | .391 |
| Liver | 6 (10) | 5 (4) | .193 | 11 (6) | 28 (5) | .567 |
| GI tract | 13 (21) | 8 (7) | .007 | 21 (12) | 80 (14) | .454 |
| GU tract | 2 (3) | 2 (2) | .61 | 4 (2) | 1 (0.5) | .014 |
| Breast | 1 (2) | 3 (3) | 1 | 4 (2) | 2 (0.5) | .034 |
| Testicles | 1 (2) | 2 (2) | 1 | 3 (2) | 4 (1) | .37 |
| Skin | 14 (22) | 20 (17) | .425 | 34 (19) | 37 (7) | <.001 |
| Bone | 7 (11) | 10 (8) | .597 | 17 (9) | 24 (4) | .014 |
| Other | 5 (8) | 1 (1) | .019 | 6 (3) | 28 (5) | .419 |
| Lung | 12 (19) | 14 (12) | .189 | 26 (14) | 29 (5) | <.001 |
| Soft tissue | 7 (11) | 6 (5) | .142 | 13 (7) | 19 (3) | .035 |
| Sinus | 4 (6) | 7 (6) | 1 | 11 (6) | 9 (2) | .003 |
| Pleura | 1 (2) | 2 (2) | 1 | 3 (2) | 27 (5) | .08 |
| Peritoneum | 3 (5) | 0 (0) | .04 | 3 (2) | 8 (1) | .734 |
| BM/PB involvement | .001 | .037 | ||||
| Yes | 26 (41) | 23 (19) | 49 (27) | 115 (20) | ||
| No | 31 (49) | 94 (79) | 125 (69) | 451 (80) | ||
| Missing | 6 (10) | 2 (2) | 8 (4) | 0 (0) | ||
| ≥2 sites of EN involvement (including BM/PB) | <.001 | <.001 | ||||
| Yes | 30 (48) | 20 (17) | 50 (27) | 79 (14) | ||
| No | 33 (52) | 99 (83) | 132 (73) | 487 (86) | ||
| IPI score | ||||||
| 0-1 | 9 (14) | 43 (36) | .002 | 52 (29) | 146 (26) | .499 |
| 2-3 | 42 (67) | 57 (48) | .019 | 99 (54) | 318 (56) | .732 |
| 4-5 | 12 (19) | 19 (16) | .679 | 31 (17) | 96 (17) | 1 |
Abbreviations are explained in Table 1.